Dermapharm has continuously optimised its business and sought external growth opportunities in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The Company's focus lies on a three-pillar strategy: developing new products in-house, expanding its international footprint and completing further acquisitions. Contact 


Investor Relations & Corporate Communications cometis AG 
Britta Hamberger                              Claudius Krause 
Tel.: +49 (0)89 - 64186-233                   Tel.: +49 (0)611 - 205855-28 
Fax: +49 (0)89 - 64186-165                    Fax: +49 (0)611 - 205855-66 
E-mail: ir@dermapharm.com                     E-mail: ir@dermapharm.com -----------------------------------------------------------------------------------------------------------------------

2021-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Dermapharm Holding SE 
              Lil-Dagover-Ring 7 
              82031 Grünwald 
              Germany 
Phone:        +49 (0)89 64 86-0 
E-mail:       ir@dermapharm.com 
Internet:     ir.dermapharm.de 
ISIN:         DE000A2GS5D8 
WKN:          A2GS5D 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Stuttgart, Tradegate Exchange 
EQS News ID:  1183605 
 
End of News   DGAP News Service 
=------------

1183605 2021-04-13

(END) Dow Jones Newswires

April 13, 2021 01:31 ET (05:31 GMT)